Founded in 2015, Micregen is developing a number of patent protected therapeutics. Micregen believe that their innovative approach and cutting edge Secretomix have the potential to change the way that multiple critical and chronic conditions are managed. 

News

2021

June
Micregen move into larger laboratory facilities, to accelerate product development
May
Micregen register new Patents for MRG1061 manufacture and for proprietary immortalised cell line
April
Micregen complete funding round to complete important milestones through ’21 and ’22
February
Micregen achieve positive results in all three target outcomes in USA DSS in vivo study
Jun
Micregen move into larger laboratory facilities, to accelerate product development
May
Micregen register new Patents for MRG1061 manufacture and for proprietary immortalised cell line
Apr
Micregen complete funding round to complete important milestones through ’21 and ’22
Feb
Micregen achieve positive results in all three target outcomes in USA DSS in vivo study

2020

October
Micregen begin collaborating with Great Ormond Street Hospital
Micregen complete 2020 funding round, led by Pitalia Private Family Office
September
Micregen begin collaborating with the University of Bradford
July
Micregen initiates cGMP manufacture project for its first therapeutic, MRG1061, in readiness for FIH clinical trials
April
Further financial support from Micregen shareholders with new equity investment, as Micregen enter an exciting phase of development
Oct
Micregen begin collaborating with Great Ormond Street Hospital
Micregen complete 2020 funding round.
Sept
Micregen begin collaborating with the University of Bradford
Jul
Micregen initiates cGMP manufacture project for its first therapeutic, MRG1061, in readiness for FIH clinical trials
Apr
Further financial support from Micregen shareholders with new equity investment, as Micregen enter an exciting phase of development

2019

December
November
Micregen welcomed its stakeholders to Alderley Park, for the annual investor meeting
Successful immortalisation of Micregen chosen cell line
July
Joanne Kelley appointed to Micregen Board
May
Jim Curtis appointed to Micregen Board
April
Micregen’s Research and Development moves into a new research lab at the Thames Valley Science Park. This marks an exciting new chapter for the company
Dec
Nov
Micregen welcomed its stakeholders to Alderley Park, for the annual investor meeting
Successful immortalisation of Micregen chosen cell line
Jul
Joanne Kelley appointed to Micregen Board
May
Jim Curtis appointed to Micregen Board
Apr
Micregen’s Research and Development moves into a new research lab at the Thames Valley Science Park. This marks an exciting new chapter for the company

2018

November
Micregen welcomed its stakeholders to Alderley Park, for the annual investor meeting
October
Micregen attend its first MHRA scientific advisory meeting for the first product under development, MRG1061
June
Micregen shareholders continue to support the company with further equity investment
January
Micregen win Smart award under the UK Government’s modern industrial strategy from Innovate UK, part of UK Research and Innovation
Nov
Micregen welcomed its stakeholders to Alderley Park, for the annual investor meeting
Oct
Micregen attend its first MHRA scientific advisory meeting for the first product under development, MRG1061
Jun
Micregen shareholders continue to support the company with further equity investment
Jan
Micregen win Smart award under the UK Government’s modern industrial strategy from Innovate UK, part of UK Research and Innovation

2017

June
April
February
Micregen welcomed its stakeholders to Alderley Park, for the annual investor meeting
Research team identify target factors for immortalisation
Micregen shareholders continue to support the company with further equity investment
Jun
Apr
Feb
Micregen welcomed its stakeholders to Alderley Park, for the annual investor meeting
Research team identify target factors for immortalisation
Micregen shareholders continue to support the company with further equity investment

2016

September
Peter Ormerod appointed as Non-Exec Director
Cary Depel appointed to Micregen Board
August
First outside equity investment into Micregen
June
Scientific team assembled
Sept
Peter Ormerod appointed as Non-Exec Director
Cary Depel appointed to Micregen Board
Aug
First outside equity investment into Micregen
Jun
Scientific team assembled

2015

August
Following twenty years of scientific stem cell research and eighteen months strategic planning, Micregen is founded by Barry Sharples and Stephen Ray
Aug
Following twenty years of scientific stem cell research and eighteen months strategic planning, Micregen is founded by Barry Sharples and Stephen Ray

Awards

In 2018, Micregen's product development potential was recognised by the British Government's Innovate UK fund. Micregen was awarded a Smart grant toward the development of MRG1061, the companies’ treatment for Necrotising Enterocolitis. ​ Funding was provided through the Government’s modern industrial strategy by Innovate UK, part of UK Research and Innovation. ​ UK Research and Innovation is a new organisation that brings together the UK Research Councils, Innovate UK and Research England into a single organisation to create the best environment for research and innovation to flourish. The vision is to ensure the UK maintains its world-leading position in research and innovation.

Expert grant assessors’ quotes include:

"This application is accompanied by a world class team to carry out the project & exploit the results"

"This is a platform technology which has potential in many diseases & success would be good for UK science"

"It is a high clinical need combined with radical innovation... there is a big upside for the UK"

CONTACT US